
SOPH Stock Forecast & Price Target
SOPH Analyst Ratings
Bulls say
Sophia Genetics is a healthcare technology company with a positive outlook, as they have a successful SaaS platform and are seeing positive momentum in their backlog, biopharma sector, and US market. With their recent deals with US health systems and plans to become profitable in the second half of 2027, they aim to achieve profitability in the medium term and have a target price of $8. The company is also expanding their partnership with the Mayo Clinic and targeting large deals, which indicates potential for further growth and success in the future.
Bears say
Sophia Genetics is facing challenges with its declining revenue per analysis, which can partially be attributed to headwinds with biopharma customers in different regions. Additionally, its main focus on capturing longitudinal patient data and building a global sales presence has not been fully valued by investors, resulting in a negative view. While the company has had some recent success in the pharmaceutical industry, it is still facing challenges in certain regions and has yet to fully capitalize on its data-driven medicine platform.
This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.
SOPH Analyst Forecast & Price Prediction
Start investing in SOPH
Order type
Buy in
Order amount
Est. shares
0 shares